Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Nicorandil on Atherosclerosis Risk in Rheumatoid Arthritis
NCT07800351Phase 3Not yet recruiting
- Sponsor
- Tanta University
- Start
- Sep 2026
- Primary completion
- Feb 2027
- Countries
- 1
01
Overview
Phase 3, randomised trial of nicorandil in atherosclerosis (2 arms), sponsored by Tanta University. Primary endpoints: Carotid Intima-Media Thickness at 13 weeks and Serum Lipoprotein(a) Level at 13 weeks. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
nicorandil
03
Conditions
atherosclerosis
Beyond the preview
Go deeper on NCT07800351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07800351.